Journal articleNPJ Vaccines · December 19, 2025
Adjuvants play an important role in modulating antigen-specific immune responses. We conducted a comparative adjuvant immunogenicity study in Rhesus macaques using HIV-1 subtype B gp120 envelope protein, B.63521, formulated with aluminum hydroxide gel (AH) ...
Full textLink to itemCite
Journal articleFront Immunol · 2025
INTRODUCTION: Hepatitis C virus (HCV) infection remains a leading cause of morbidity and mortality in people with human immunodeficiency virus (HIV). Liver fibrosis progression is more rapid in people with HIV/HCV coinfection compared to HCV monoinfection ...
Full textLink to itemCite
Journal articleJ Clin Invest · November 12, 2024
Human cytomegalovirus (HCMV) profoundly impacts host T and NK cells across the lifespan, yet how this common congenital infection modulates developing fetal immune cell compartments remains underexplored. Using cord blood from neonates with and without con ...
Full textLink to itemCite
Journal articleMucosal Immunol · August 2024
Immunoglobulin A (IgA) is the predominant mucosal antibody class with both anti- and pro-inflammatory roles1-3. However, the specific role of the IgA receptor cluster of differentiation (CD)89, expressed by a subset of natural killer (NK) cells, is poorly ...
Full textLink to itemCite
Book section · January 1, 2024
Antigen-specific Cytotoxic T Lymphocytes (CTLs) can be detected by measuring responsiveness to major histocompatibility complex class I (MHC-I)-presented peptide as the ability to produce cytokines/chemokines or to eliminate target cells. Functional assays ...
Full textCite
Journal articleScience (New York, N.Y.) · December 2023
Current HIV vaccines designed to stimulate CD8+ T cells have failed to induce immunologic control upon infection. The functions of vaccine-induced HIV-specific CD8+ T cells were investigated here in detail. Cytotoxic capacity was sign ...
Full textCite
Journal articleNPJ Vaccines · November 24, 2023
An effective HIV-1 vaccine remains a critical unmet need for ending the AIDS epidemic. Vaccine trials conducted to date have suggested the need to increase the durability and functionality of vaccine-elicited antibodies to improve efficacy. We hypothesized ...
Full textOpen AccessLink to itemCite